Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.
Streptococcus suis
heterologous antigens
outer membrane vesicles (OMVs)
protective immunity
vaccine
Journal
Applied and environmental microbiology
ISSN: 1098-5336
Titre abrégé: Appl Environ Microbiol
Pays: United States
ID NLM: 7605801
Informations de publication
Date de publication:
29 03 2023
29 03 2023
Historique:
medline:
31
3
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Bacterial outer membrane vesicles (OMVs) are considered a promising vaccine platform for their high built-in adjuvanticity and ability to efficiently induce immune responses. OMVs can be engineered with heterologous antigens based on genetic engineering strategies. However, several critical issues should still be validated, including optimal exposure to the OMV surface, increased production of foreign antigens, nontoxicity, and induction of powerful immune protection. In this study, engineered OMVs with the lipoprotein transport machinery (Lpp) were designed to present SaoA antigen as a vaccine platform against Streptococcus suis. The results suggest that Lpp-SaoA fusions can be delivered on the OMV surface and do not have significant toxicity. Moreover, they can be engineered as lipoprotein and significantly accumulated in OMVs at high levels, thus accounting for nearly 10% of total OMV proteins. Immunization with OMVs containing Lpp-SaoA fusion antigen induced strong specific antibody responses and high levels of cytokines, as well as a balanced Th1/Th2 immune response. Furthermore, the decorated OMV vaccination significantly enhanced microbial clearance in a mouse infection model. It was found that antiserum against lipidated OMVs significantly promoted the opsonophagocytic uptake of S. suis in RAW246.7 macrophages. Lastly, OMVs engineered with Lpp-SaoA induced 100% protection against a challenge with 8× the 50% lethal dose (LD
Identifiants
pubmed: 36809058
doi: 10.1128/aem.02047-22
pmc: PMC10057044
doi:
Substances chimiques
Antigens, Heterophile
0
Bacterial Outer Membrane Proteins
0
Vaccines
0
Lipoproteins
0
Antibodies, Bacterial
0
Bacterial Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0204722Références
J Mol Biol. 2008 Jun 27;380(1):51-66
pubmed: 18511069
Infect Immun. 2006 Jan;74(1):305-12
pubmed: 16368985
Infect Immun. 2008 Jul;76(7):3241-54
pubmed: 18458067
Mucosal Immunol. 2017 Jan;10(1):250-259
pubmed: 27118490
Nat Rev Microbiol. 2015 Oct;13(10):605-19
pubmed: 26373371
Emerg Infect Dis. 2011 Jan;17(1):7-15
pubmed: 21192848
J Innate Immun. 2017;9(2):162-180
pubmed: 27855374
Virulence. 2017 Oct 3;8(7):1274-1289
pubmed: 28362221
Future Microbiol. 2012 Feb;7(2):259-79
pubmed: 22324994
Biochem J. 1965 Aug;96(2):567-76
pubmed: 4953781
Vet Microbiol. 2010 Jul 14;143(2-4):363-70
pubmed: 20044219
Expert Rev Vaccines. 2015;14(12):1587-608
pubmed: 26468755
mBio. 2019 Nov 26;10(6):
pubmed: 31772056
Nat Rev Immunol. 2011 Nov 04;11(12):865-72
pubmed: 22051890
Clin Exp Immunol. 2019 Jun;196(3):287-304
pubmed: 30985006
Eur J Immunol. 1995 Mar;25(3):823-9
pubmed: 7705414
Virulence. 2019 Dec;10(1):82-96
pubmed: 31874075
J Biol Chem. 2004 Jan 16;279(3):2069-76
pubmed: 14578354
Infect Immun. 2002 Apr;70(4):1739-49
pubmed: 11895935
J Biol Chem. 1981 Feb 25;256(4):1604-7
pubmed: 6257680
Annu Rev Microbiol. 2010;64:163-84
pubmed: 20825345
Vaccine. 2015 Apr 21;33(17):2022-9
pubmed: 25776921
Microbiol Mol Biol Rev. 2010 Mar;74(1):81-94
pubmed: 20197500
Proteomics. 2009 Dec;9(24):5425-36
pubmed: 19834908
NPJ Vaccines. 2021 Jan 29;6(1):18
pubmed: 33514749
PLoS Negl Trop Dis. 2018 Aug 22;12(8):e0006701
pubmed: 30133440
Clin Vaccine Immunol. 2007 Aug;14(8):937-43
pubmed: 17567767
Adv Drug Deliv Rev. 2017 May 15;114:132-142
pubmed: 28501509
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104
pubmed: 20133740
J Immunol Res. 2014;2014:619410
pubmed: 25057505
J Immunol. 2007 Dec 1;179(11):7692-701
pubmed: 18025215
Vaccine. 2015 Sep 11;33(38):4858-67
pubmed: 26238722
Nat Rev Microbiol. 2019 Jan;17(1):13-24
pubmed: 30397270
Science. 1990 Oct 26;250(4980):553-6
pubmed: 2237407
Adv Drug Deliv Rev. 2009 Mar 28;61(3):243-7
pubmed: 19174176
J Extracell Vesicles. 2014 Aug 11;3:
pubmed: 25147647
Vaccine. 1995 Aug;13(12):1086-94
pubmed: 7491816
AMB Express. 2022 Jan 25;12(1):5
pubmed: 35075554
Nat Commun. 2021 Apr 6;12(1):2041
pubmed: 33824314
J Biol Chem. 1972 Dec 25;247(24):8154-9
pubmed: 4565677
Mol Microbiol. 2011 Mar;79(5):1168-81
pubmed: 21219470
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21780-21788
pubmed: 31591215
mSphere. 2021 Oct 27;6(5):e0069921
pubmed: 34612675
J Extracell Vesicles. 2021 Feb;10(4):e12066
pubmed: 33643549
Avian Dis. 1999 Jul-Sep;43(3):429-41
pubmed: 10494411
Vet Res. 2017 Dec 21;48(1):89
pubmed: 29268787
Res Microbiol. 1990 Sep-Oct;141(7-8):839-50
pubmed: 2101473
Vaccine. 2009 Jun 24;27 Suppl 2:B3-12
pubmed: 19481313
Genes Dev. 2005 Nov 15;19(22):2645-55
pubmed: 16291643
Vaccine. 2009 Nov 12;27(48):6748-54
pubmed: 19748581
Biotechnol Adv. 2017 Sep;35(5):565-574
pubmed: 28522212
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
J Extracell Vesicles. 2013 May 06;2:
pubmed: 24009891
PLoS One. 2015 Jun 25;10(6):e0130528
pubmed: 26110524